Basaloid/follicular hyperplasia overlying connective tissue/mesenchymal hamartomas simulating basal cell carcinomas

Stashower, Mitchell E.; Smith, Kathleen J.; Corbett, David W.; Skelton, Henry G.

doi:10.1067/mjd.2001.117727

Cited by 24 publications

(15 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These CD34‐reactive cells have been reported to be an intrinsic component of the lesion, together with smooth muscle fascicles, nerve fibers and hair follicles 66 . CD34 immunostaining has also been reported in other types of connective tissue/mesenchymal hamartomas, 67 including dermal dendrocyte hamartoma with stubby white hair, 68 congenital cutaneous granular cell tumors, 69,70 medallion‐like dermal dendrocyte hamartoma 71,72 and polypoid dermal dendrocytic hamartoma 73 …”

Section: Fibroblastic Fibrohistiocytic and Myofibroblastic Lesionsmentioning

confidence: 96%

CD34‐reactive tumors of the skin. An updated review of an ever‐growing list of lesions

Tardío

2008

J Cutan Pathol

View full text Add to dashboard Cite

Section: Fibroblastic Fibrohistiocytic and Myofibroblastic Lesionsmentioning

confidence: 96%

CD34‐reactive tumors of the skin. An updated review of an ever‐growing list of lesions

Tardío

2008

J Cutan Pathol

View full text Add to dashboard Cite

“…Studies have had mixed results regarding the utility of Ki-67 and p53 for distinguishing BCC from FI. 25,28,[39][40][41] Similar to benign follicular tumors, FI will demonstrate colonization by CK20…”

Section: Follicular Induction Over Dermatofibromamentioning

confidence: 99%

Histologic Mimics of Basal Cell Carcinoma

Stanoszek

Wang

Harms

2017

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.— Basal cell carcinoma (BCC) is the most common human malignant neoplasm and is a frequently encountered diagnosis in dermatopathology. Although BCC may be locally destructive, it rarely metastasizes. Many diagnostic entities display morphologic and immunophenotypic overlap with BCC, including nonneoplastic processes, such as follicular induction over dermatofibroma; benign follicular tumors, such as trichoblastoma, trichoepithelioma, or basaloid follicular hamartoma; and malignant tumors, such as sebaceous carcinoma or Merkel cell carcinoma. Thus, misdiagnosis has significant potential to result in overtreatment or undertreatment. Objective.— To review key features distinguishing BCC from histologic mimics, including current evidence regarding immunohistochemical markers useful for that distinction. Data Sources.— Review of pertinent literature on BCC immunohistochemistry and differential diagnosis. Conclusions.— In most cases, BCC can be reliably diagnosed by histopathologic features. Immunohistochemistry may provide useful ancillary data in certain cases. Awareness of potential mimics is critical to avoid misdiagnosis and resulting inappropriate management.

show abstract

“…We believe that we can extend our conclusions to BCC in general, because so far all clinicopathologic variants of BCC (eg, morpheiform, nodular, infiltrative, cystic, adenoid, granular) have been shown to consistently express Ep-CAM, as highlighted on staining with Ber-EP4. 10,14,[24][25][26][27] Interestingly, areas of basaloid hyperplasia overlying connective tissue hamartomas 28 and organoid nevi 29 have also been shown to be positive for Ber-EP4. The equivalent structures overlying the dermal component of some dermatofibromas react in an analogous manner (personal observation, unpublished).…”

Section: Discussionmentioning

confidence: 98%